Paper29637482
Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
Su J and 2 others. Clin Rheumatol, 2018. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis. Papers, record 29637482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29637482
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Hepatitis B virus | Major topic |
| Hepatitis B, Chronic | Major topic |
| Rheumatic Diseases | Major topic |
| Virus Activation | Major topic |
| Antirheumatic Agents | |
| Humans | |
| Lamivudine | |
| Randomized Controlled Trials as Topic | |
| Reproducibility of Results | |
| Risk | |
| Sensitivity and Specificity |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28128861 | Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. | Hepatology | 2017 | https://conductscience.org/library/papers/28128861 | PubMed |
| 2 | 26819537 | Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations. | World J Gastroenterol | 2016 | https://conductscience.org/library/papers/26819537 | PubMed |
| 3 | 22460162 | Barriers to treatment of hepatitis B in an urban Chinatown community. | J Clin Gastroenterol | 2012 | https://conductscience.org/library/papers/22460162 | PubMed |
| 4 | 25678179 | The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. | J Formos Med Assoc | 2015 | https://conductscience.org/library/papers/25678179 | PubMed |
| 5 | 18302293 | A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. | Hepatology | 2008 | https://conductscience.org/library/papers/18302293 | PubMed |
| 6 | 19729084 | Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. | Vaccine | 2009 | https://conductscience.org/library/papers/19729084 | PubMed |
| 7 | 16440366 | Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. | Hepatology | 2006 | https://conductscience.org/library/papers/16440366 | PubMed |
| 8 | 27291888 | Prevention of Hepatitis B reactivation in the setting of immunosuppression. | Clin Mol Hepatol | 2016 | https://conductscience.org/library/papers/27291888 | PubMed |
| 9 | 18378948 | Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. | Ann Intern Med | 2008 | https://conductscience.org/library/papers/18378948 | PubMed |
| 10 | 11722410 | Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. | Br J Haematol | 2001 | https://conductscience.org/library/papers/11722410 | PubMed |
| 11 | 26545940 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. | Arthritis Rheumatol | 2016 | https://conductscience.org/library/papers/26545940 | PubMed |
| 12 | 25447850 | American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. | Gastroenterology | 2015 | https://conductscience.org/library/papers/25447850 | PubMed |
| 13 | 26057738 | Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis. | PLoS One | 2015 | https://conductscience.org/library/papers/26057738 | PubMed |
| 14 | 27450506 | Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. | Int J Clin Pharm | 2016 | https://conductscience.org/library/papers/27450506 | PubMed |
| 15 | 25199680 | Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis. | Clin Res Hepatol Gastroenterol | 2015 | https://conductscience.org/library/papers/25199680 | PubMed |
| 16 | 22273662 | Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. | Vaccine | 2012 | https://conductscience.org/library/papers/22273662 | PubMed |
| 17 | 19714720 | Chronic hepatitis B: update 2009. | Hepatology | 2009 | https://conductscience.org/library/papers/19714720 | PubMed |
| 18 | 12774010 | Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. | Hepatology | 2003 | https://conductscience.org/library/papers/12774010 | PubMed |
| 19 | 25532827 | Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. | BMC Musculoskelet Disord | 2014 | https://conductscience.org/library/papers/25532827 | PubMed |
| 20 | 25114684 | HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. | Int J Rheumatol | 2014 | https://conductscience.org/library/papers/25114684 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42370076 | Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region. | EULAR Rheumatol Open | 2026 | https://conductscience.org/library/papers/42370076 | PubMed |
| 36323488 | Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. | RMD Open | 2022 | https://conductscience.org/library/papers/36323488 | PubMed |
| 34200522 | Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. | J Clin Med | 2021 | https://conductscience.org/library/papers/34200522 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29637482
GET https://conductscience.org/api/papers/v1/29637482/references?page=2